Loading...
Docoh

Cortexyme (CRTX)

News

From Benzinga Pro
Credit Suisse Maintains Underperform on Cortexyme, Lowers Price Target to $3.5
11 May 22
News, Price Target, Analyst Ratings
Credit Suisse analyst Judah Frommer maintains Cortexyme (NASDAQ:CRTX) with a Underperform and lowers the price target from $4 to $3.5.
103 Biggest Movers From Yesterday
11 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
77 Stocks Moving In Tuesday's Mid-Day Session
10 May 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
10 May 22
Biotech, Earnings, M&A, News, Penny Stocks, Guidance, Health Care, Financing, Offerings, Small Cap, FDA, Management, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Cortexyme Announces Agreement To Acquire Novosteo; Terms Not Disclosed
10 May 22
M&A
Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
4 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Wednesday's trading, 435 companies set new 52-week lows.
Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves
3 May 22
Biotech, News, Penny Stocks, Health Care, General
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
3 May 22
Biotech, Earnings, News, Penny Stocks, Guidance, Health Care, Financing, Offerings, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
25 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 721 companies achieved new lows for the year.
Stocks That Hit 52-Week Lows On Friday
22 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 431 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
21 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 236 companies hit new 52-week lows.
Cortexyme Provides New GAIN Trial Data At AD/PD 2022 Demonstrating Potential Benefit Of Lysine Gingipain Inhibition In Mild To Moderate Alzheimer's Population
21 Mar 22
News
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, presented new target engagement
Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits Of Atuzaginstat For The Treatment Of High-Risk Oral Potentially Malignant Disorders
9 Mar 22
News, FDA
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today provided an update on both
10 Biggest Price Target Changes For Wednesday
9 Mar 22
Penny Stocks, Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Telsey Advisory Group cut the price target on Stitch Fix, Inc. (NASDAQ: SFIX) from $25 to $14. Stitch Fix shares fell 24.5% to $8.31 in pre-market trading.
HC Wainwright & Co. Maintains Buy on Cortexyme, Lowers Price Target to $15
9 Mar 22
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Andrew Fein maintains Cortexyme (NASDAQ:CRTX) with a Buy and lowers the price target from $30 to $15.
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
8 Mar 22
Biotech, News, Penny Stocks, Health Care, Movers, Trading Ideas, General
Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.
Cortexyme Reports Safety And Pharmacokinetics Results From Single Ascending Dose Portion Of Its Phase 1 Clinical Trial Of COR588; Says OR588 Well-Tolerated In All Dose Cohorts
8 Mar 22
Biotech, General
COR588 well-tolerated in all dose cohorts Human pharmacokinetics support once daily oral dosing Multiple ascending dose data expected in the second quarter of 2022 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Stocks That Hit 52-Week Lows On Wednesday
23 Feb 22
On Wednesday, 348 companies hit new 52-week lows.

Press releases

From Benzinga Pro
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
20 May 22
Press Releases
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr.
Cortexyme Successfully Completes Acquisition of Novosteo
20 May 22
Press Releases
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
12 May 22
Press Releases
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will
Cortexyme Announces Agreement to Acquire Novosteo
10 May 22
Press Releases
Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen
Bragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm
6 May 22
News, Legal, Press Releases
NEW YORK, May 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agrify Corporation (NASDAQ:AGFY), CareDx, Inc.
Bragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and Corcept and Encourages Investors to Contact the Firm
1 May 22
News, Legal, Press Releases
NEW YORK, May 01, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CareDx, Inc. (NASDAQ:CDNA), Medallion Financial
Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
28 Apr 22
News, Legal, Press Releases
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Cortexyme, Inc. (NASDAQ:CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Cortexyme (CRTX) for Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm's Attorneys
26 Apr 22
News, Legal, Press Releases
SAN FRANCISCO, April 26, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Cortexyme, Inc. (NASDAQ:CRTX) investors who suffered significant losses to submit your losses now. The firm is investigating possible securities law
Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Corcept, RBB, and Verra and Encourages Investors to Contact the Firm
25 Apr 22
News, Legal, Press Releases
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cortexyme, Inc. (NASDAQ:CRTX), Corcept
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
25 Apr 22
Press Releases
NEW YORK, April 25, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to contact
Thinking about buying stock in Cortexyme, Borqs Technologies, Sundial Growers, Nokia, or Nordic American Tanker?
25 Apr 22
Opinion, Press Releases
NEW YORK, April 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRTX, BRQS, SNDL, NOK, and NAT.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cortexyme, Inc. - CRTX
21 Apr 22
Press Releases
New York, New York--(Newsfile Corp. - April 21, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to contact
Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
21 Apr 22
News, Legal, Press Releases
BOSTON, April 21, 2022 (GLOBE NEWSWIRE) -- Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm BOSTON -- Block
Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, SelectQuote, Corcept, and Core Scientific and Encourages Investors to Contact the Firm
20 Apr 22
News, Legal, Press Releases
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cortexyme, Inc. (NASDAQ:CRTX), SelectQuote,
CIR INVESTIGATION: Hagens Berman, National Trial Attorneys, Investigating Cortexyme (CRTX) for Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm
20 Apr 22
Press Releases
SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Cortexyme, Inc. (NASDAQ:CRTX) investors who suffered significant losses to submit your losses now. The firm is investigating possible securities law
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
19 Apr 22
News, Legal, Press Releases
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to contact Robert S.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
17 Apr 22
Legal, Press Releases
NEW YORK, NY / ACCESSWIRE / April 17, 2022 / Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to
Bragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and SelectQuote and Encourages Investors to Contact the Firm
15 Apr 22
News, Legal, Press Releases
NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CareDx, Inc. (NASDAQ:CDNA), Medallion
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
15 Apr 22
News, Legal, Press Releases
NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to contact Robert S.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
13 Apr 22
Legal, Press Releases
NEW YORK, NY / ACCESSWIRE / April 13, 2022 / Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ:CRTX). Such investors are advised to